Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
Date:11/3/2008

------------------------------------------

Squamous Cell 3x10(9) 3 Minor response

Carcinoma 26% reduction in

Head and Neck lymph node

-------------------------------------------------------------------------

Unknown 3x10(9) 6 SD

-------------------------------------------------------------------------

Pancreas 3x10(10) 6* SD

-------------------------------------------------------------------------

Prostate 3x10(10) 5* SD

-------------------------------------------------------------------------

Prostate 3x10(10) 5 SD

-------------------------------------------------------------------------

Melanoma 1x10(10) 4 SD

-------------------------------------------------------------------------

Pancreas 3x10(10) 2 SD, but progressed

clinically

-------------------------------------------------------------------------

* patients still on study. CR=complete response,

PR=partial response, SD=stable disease

"These are extraordinary results for a Phase I trial," said Dr. Brad Thompson, President and CEO of Oncolytics. "To see tumour stabilization or better in this patient population is highly unusual."

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. In this portion of the trial, which was completed in August 2008, standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a f
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
2. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
4. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
5. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
6. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
8. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email: